Bortezomib plus Melphalan and Prednisone for Multiple Myeloma
Patients who received the three-drug front-line therapy achieved higher response rates and longer time to disease progression than did those who received melphalan and prednisone alone.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)